Skip to content

A Multiple Dose Pharmacokinetic Study of AMX0035 in Participants with Impaired Renal Function and in Healthy Participants

Status
Completed
Phases
Phase 1
Study type
Interventional
Source
EU CTIS
Registry ID
CTIS2023-504393-37-00
Acronym
A35-015
Enrollment
32
Registered
2023-08-23
Start date
2023-10-31
Completion date
2024-03-06
Last updated
2024-02-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy volunteers, Volunteers with Renal Impairment

Interventions

None listed

Sponsors

Amylyx Pharmaceuticals EMEA B.V., Amylyx Pharmaceuticals Inc.
Lead SponsorINDUSTRY

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Countries

Bulgaria

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026